ArticleIBRO neuroscience reports2026
Ketamine preserves perineuronal nets in chronic stressed mice brain through the inhibition of microglia activation.
Article in IBRO neuroscience reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Deeper understanding of ketamine's mechanism of action would contribute to the discovery of novel therapeutic targets with fast-onset actions. To gain insight on the mechanism underlying the antidepressant-like effects of ketamine, we focused on perineuronal nets (PNNs), an extracellular matrix structure that surrounds fast-spiking parvalbumin-positive interneurons and regulates synaptic plasticity, whose integrity is known to be compromised under stress-induced depressive conditions. Methods: We first performed the description of the plastic remodeling of PNNs in the Chronic restraint stress (CRS) mice treated or un-treated with ketamine, by quantifying the number of WFA, marker of PNNs, parvalbumin (PV) and c-Fos positive cells, as a surrogate of neuronal activity. And then, we investigated the the transcripts of a number of proteins involved in the formation or degradation of PNNs with or without ketamine in CRS mice. Next, we evaluated the expression of IBA1, a microglial marker, in the hippocampus and medial prefrontal cortex after CRS treated or un-treated with ketamine. Results: We found that ketamine effectively alleviated the animals' depression like behavior as well as attenuates CRS-induced reduction of WFA-positive cells in the hippocampus and medial prefrontal cortex of mice. Although ketamine treatment had little or no effect on the number of PV, c-Fos positive cells and the transcripts of proteins involved in the formation or degradation of PNNs. Notably, ketamine treatment lead to remarkably reduced the number of IBA1-positive cells in the hippocampus and medial prefrontal cortex after CRS. Conclusion: Our findings suggest that PNNs is characterized by region-specific changes in chronic stress mouse brain and provide extensive evidence that ketamine exposure initiates microglia to remodel PNN, instead of the PNN accumulation and degradation enzymes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.